Cargando…

Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)

BACKGROUND: Polycystic kidney disease with hyperinsulinaemic hypoglycaemia (HIPKD) is a recently described disease caused by a single nucleotide variant, c.‐167G>T, in the promoter region of PMM2 (encoding phosphomannomutase 2), either in homozygosity or compound heterozygosity with a pathogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Islam, Sumaya, Tekman, Mehmet, Flanagan, Sarah E., Guay‐Woodford, Lisa, Hussain, Khalid, Ellard, Sian, Kleta, Robert, Bockenhauer, Detlef, Stanescu, Horia, Iancu, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683636/
https://www.ncbi.nlm.nih.gov/pubmed/33811480
http://dx.doi.org/10.1002/mgg3.1674
_version_ 1784617459018366976
author Islam, Sumaya
Tekman, Mehmet
Flanagan, Sarah E.
Guay‐Woodford, Lisa
Hussain, Khalid
Ellard, Sian
Kleta, Robert
Bockenhauer, Detlef
Stanescu, Horia
Iancu, Daniela
author_facet Islam, Sumaya
Tekman, Mehmet
Flanagan, Sarah E.
Guay‐Woodford, Lisa
Hussain, Khalid
Ellard, Sian
Kleta, Robert
Bockenhauer, Detlef
Stanescu, Horia
Iancu, Daniela
author_sort Islam, Sumaya
collection PubMed
description BACKGROUND: Polycystic kidney disease with hyperinsulinaemic hypoglycaemia (HIPKD) is a recently described disease caused by a single nucleotide variant, c.‐167G>T, in the promoter region of PMM2 (encoding phosphomannomutase 2), either in homozygosity or compound heterozygosity with a pathogenic coding variant in trans. All patients identified so far are of European descent, suggesting a possible founder effect. METHODS: We generated high density genotyping data from 11 patients from seven unrelated families, and used this information to identify a common haplotype that included the promoter variant. We estimated the age of the promoter mutation with DMLE+ software, using demographic parameters corresponding to the European population. RESULTS: All patients shared a 0.312 Mb haplotype which was absent in 503 European controls available in the 1000 Genomes Project. The age of this mutation was estimated as 105–110 generations, indicating its occurrence around 600 BC, a time of intense migration, which might explain the presence of the same mutations in Europeans around the globe. CONCLUSION: The shared unique haplotype among seemingly unrelated patients is consistent with a founder effect in Europeans.
format Online
Article
Text
id pubmed-8683636
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86836362021-12-30 Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD) Islam, Sumaya Tekman, Mehmet Flanagan, Sarah E. Guay‐Woodford, Lisa Hussain, Khalid Ellard, Sian Kleta, Robert Bockenhauer, Detlef Stanescu, Horia Iancu, Daniela Mol Genet Genomic Med Original Articles BACKGROUND: Polycystic kidney disease with hyperinsulinaemic hypoglycaemia (HIPKD) is a recently described disease caused by a single nucleotide variant, c.‐167G>T, in the promoter region of PMM2 (encoding phosphomannomutase 2), either in homozygosity or compound heterozygosity with a pathogenic coding variant in trans. All patients identified so far are of European descent, suggesting a possible founder effect. METHODS: We generated high density genotyping data from 11 patients from seven unrelated families, and used this information to identify a common haplotype that included the promoter variant. We estimated the age of the promoter mutation with DMLE+ software, using demographic parameters corresponding to the European population. RESULTS: All patients shared a 0.312 Mb haplotype which was absent in 503 European controls available in the 1000 Genomes Project. The age of this mutation was estimated as 105–110 generations, indicating its occurrence around 600 BC, a time of intense migration, which might explain the presence of the same mutations in Europeans around the globe. CONCLUSION: The shared unique haplotype among seemingly unrelated patients is consistent with a founder effect in Europeans. John Wiley and Sons Inc. 2021-04-03 /pmc/articles/PMC8683636/ /pubmed/33811480 http://dx.doi.org/10.1002/mgg3.1674 Text en © 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Islam, Sumaya
Tekman, Mehmet
Flanagan, Sarah E.
Guay‐Woodford, Lisa
Hussain, Khalid
Ellard, Sian
Kleta, Robert
Bockenhauer, Detlef
Stanescu, Horia
Iancu, Daniela
Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)
title Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)
title_full Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)
title_fullStr Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)
title_full_unstemmed Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)
title_short Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)
title_sort founder mutation in the pmm2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (hipkd)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683636/
https://www.ncbi.nlm.nih.gov/pubmed/33811480
http://dx.doi.org/10.1002/mgg3.1674
work_keys_str_mv AT islamsumaya foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT tekmanmehmet foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT flanagansarahe foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT guaywoodfordlisa foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT hussainkhalid foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT ellardsian foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT kletarobert foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT bockenhauerdetlef foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT stanescuhoria foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd
AT iancudaniela foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd